Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript